FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1926-1928 June 17, 1999 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Navari, R. M. PubMed Citation

To the Editor: The study by Navari et al. (Jan. 21 issue)¹ of the ability of a new, selective neurokinin-1–receptor antagonist, L-754,030, to prevent cisplatin-induced acute and delayed emesis has two important shortcomings. First, the ability of L-754,030 to prevent delayed emesis was compared with that of placebo. There is clear evidence, recognized by the authors themselves, that the combination of metoclopramide or a serotonin antagonist with dexamethasone is superior to placebo in protecting cisplatin-treated patients from delayed emesis. Therefore, there is a consensus that patients who are receiving high-dose cisplatin should be given prophylaxis against delayed emesis.² Were the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• The Italian Group for Antiemetic Research, (2000). Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. NEJM 342: 1554-1559 [Abstract] [Full Text]